無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

睡眠補助の世界市場 - 世界的機会分析と産業予測

Sleep Aids Market by Product and Sleep Disorder - Global Opportunity Analysis and Industry Forecast, 2017-2023

発行 Allied Market Research 商品コード 498836
出版日 ページ情報 英文 120 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.67円で換算しております。
Back to Top
睡眠補助の世界市場 - 世界的機会分析と産業予測 Sleep Aids Market by Product and Sleep Disorder - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日: 2017年04月01日 ページ情報: 英文 120 Pages
概要

当レポートでは、睡眠補助の世界市場に注目し、需給規模の推移を、製品、睡眠障害の種類および地域の別に分析・予測するほか、市場発展の推進・抑制要因、競合環境、主要参入企業などについての最新情報を集めています。

第1章 イントロダクション

  • レポート解説
  • 主要利点
  • 主要市場セグメント
  • 調査方法
    • 二次情報収集
    • 一次情報取材
    • 分析ツールおよびモデル

第2章 エグゼクティブサマリー

  • 経営トップの視点

第3章 市場概要

  • 市場の定義と範囲
  • 主要利点
    • 主な投資ポケット
    • 主な成功戦略
  • 特許分析
    • 年次別特許分析
    • 地域別特許分析
    • 睡眠障害別特許分析
  • 行政府規制
    • U.S. FDA
    • Europe CE Mark
    • Ministry of Health, Labor, and Welfare (MHLW)
  • 主要企業ポジショニング:2016年
  • 市場動態
    • 推進要因
    • 抑制要因
    • 機会

第4章 睡眠補助の世界市場 - 製品種別

  • 概要
    • 市場の規模と予測
  • マットレス・枕類
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測
  • 睡眠検査施設
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測
  • 薬剤
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測
    • 処方薬
    • 市販薬
  • 睡眠時無呼吸症治療器
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測

第5章 睡眠補助の世界市場 - 睡眠障害別

  • 概要
    • 市場の規模と予測
  • 不眠症
    • 市場の規模と予測
  • 睡眠時無呼吸症
    • 市場の規模と予測
  • 下肢静止不能症候群
    • 市場の規模と予測
  • ナルコレプシー(発作性睡眠)
    • 市場の規模と予測
  • 夢遊病
    • 市場の規模と予測
  • その他
    • 市場の規模と予測

第6章 睡眠補助の世界市場 - 地域別

  • 概要
    • 市場の規模と予測
  • 北米
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測
  • 欧州
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測
  • アジア太平洋州
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測
  • 中南米・中東・アフリカ
    • 重要市場動向
    • 重要成長ファクターおよび機会
    • 市場の規模と予測

第7章 企業プロファイル

図表

List of Tables

  • TABLE 1. GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 2. SLEEP AIDS MATTRESS AND PILLOWS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 3. SLEEP AIDS SLEEP LABORATORIES MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 4. SLEEP AIDS MEDICATIONS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 5. SLEEP AIDS PRESCRIPTION-BASED DRUGS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 6. SLEEP AIDS OTC DRUGS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 7. GLOBAL SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
  • TABLE 8. INSOMNIA SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 9. SLEEP APNEA SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 10. RESTLESS LEGS SYNDROME SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 11. NARCOLEPSY SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 12. SLEEPWALKING MEDICAL SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 13. OTHER SLEEP DISORDERS SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
  • TABLE 14. NORTH AMERICA SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 15. NORTH AMERICA SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
  • TABLE 16. NORTH AMERICA SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
  • TABLE 17. NORTH AMERICA SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 18. EUROPE SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 19. EUROPE SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
  • TABLE 20. EUROPE SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
  • TABLE 21. EUROPE SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 22. ASIA-PACIFIC SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 23. ASIA-PACIFIC SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
  • TABLE 24. ASIA-PACIFIC SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
  • TABLE 25. ASIA-PACIFIC SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 26. LAMEA SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
  • TABLE 27. LAMEA SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
  • TABLE 28. LAMEA SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
  • TABLE 29. LAMEA SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 30. CADWELL: COMPANY SNAPSHOT
  • TABLE 31. CADWELL: OPERATING SEGMENTS
  • TABLE 32. CADWELL: PRODUCT PORTFOLIO
  • TABLE 33. COMPUMEDICS: COMPANY SNAPSHOT
  • TABLE 34. COMPUMEDICS: OPERATING SEGMENTS
  • TABLE 35. DRIVE DEVILBISS HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 36. DRIVE DEVILBISS HEALTHCARE: OPERATING SEGMENTS
  • TABLE 37. DRIVE DEVILBISS HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 38. GSK: COMPANY SNAPSHOT
  • TABLE 39. GSK: OPERATING SEGMENTS
  • TABLE 40. MERCK: COMPANY SNAPSHOT
  • TABLE 41. MERCK: OPERATING SEGMENTS
  • TABLE 42. NATUS: PRODUCT PORTFOLIO
  • TABLE 43. NATUS: COMPANY SNAPSHOT
  • TABLE 44. NATUS: OPERATING SEGMENTS
  • TABLE 45. PFIZER: COMPANY SNAPSHOT
  • TABLE 46. PFIZER: OPERATING SEGMENTS
  • TABLE 47. PFIZER: PRODUCT PORTFOLIO
  • TABLE 48. PHILIPS: COMPANY SNAPSHOT
  • TABLE 49. PHILIPS: OPERATING SEGMENTS
  • TABLE 50. PHILIPS: PRODUCT PORTFOLIO
  • TABLE 51. SANOFI: COMPANY SNAPSHOT
  • TABLE 52. SANOFI: PRODUCT PORTFOLIO
  • TABLE 53. SLEEPMED: COMPANY SNAPSHOT
  • TABLE 54. SLEEPMED: OPERATING SEGMENTS
  • TABLE 55. SLEEPMED: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 1. MARKET SEGMENTATION
  • FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL SLEEP AIDS MARKET
  • FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2015-2017) (%)
  • FIGURE 4. TOP WINNING STRATEGIES IN SLEEP AIDS MARKET (2015-2017)
  • FIGURE 5. TOP WINNING STRATEGIES: TYPE AND NATURE
  • FIGURE 11. TOP PLAYER POSITIONING: GLOBAL SLEEP AIDS MARKET, 2016
  • FIGURE 12. GLOBAL SLEEP AIDS MARKET: RESTRAINTS AND DRIVERS
  • FIGURE 13. GLOBAL SLEEP AIDS MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 14. U.S. SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 15. CANADA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 16. MEXICO SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 17. GERMANY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 18. FRANCE SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 19. UK SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 20. ITALY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 21. REST OF EUROPE SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 22. JAPAN SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 23. CHINA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 24. AUSTRALIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 25. INDIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 26. REST OF ASIA-PACIFIC SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 27. BRAZIL SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 28. TURKEY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 29. SAUDI ARABIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 30. SOUTH AFRICA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 31. REST OF LAMEA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
  • FIGURE 32. CADWELL: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 33. CADWELL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 34. COMPUMEDICS: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 35. COMPUMEDICS: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 36. DRIVE DEVILBISS HEALTHCARE: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 37. DRIVE DEVILBISS HEALTHCARE: REVENUE SHARE BY PRODUCT TYPE, 2016 (%)
  • FIGURE 38. DRIVE DEVILBISS HEALTHCARE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 39. GSK: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 40. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 41. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 42. MERCK: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 43. MERCK: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 44. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 45. NATUS: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 46. NATUS: REVENUE SHARE BY GEOGRAPHY, 2015 (%)
  • FIGURE 47. PFIZER: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 48. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 49. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 50. PHILIPS: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 51. PHILIPS: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 52. PHILIPS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 53. SANOFI: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 54. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 55. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 56. SLEEPMED: REVENUE, 2016-2016 ($MILLION)
  • FIGURE 57. SLEEPMED: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 58. SLEEPMED: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
目次
Product Code: LI 171533

Sleep aids are drugs and devices that are used to diagnose and treat sleep disorders, such as sleep apnea and insomnia. Sleep disorders are caused due to substance misuse, stressful work environment, and inconsistent sleep pattern. Sleep aids help to improve the quality of sleep by reducing the time required to fall asleep and increasing the duration of quality sleep. The global sleep aids market was valued at $49,543 million in 2016, and is estimated to reach $79,851 million by 2022, registering a CAGR of 7.0% from 2017 to 2023.

The global sleep aids market is segmented based on product, sleep disorder, and geography. Based on product, it is categorized into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. The medications segment is further divided into prescription-based drugs, over-the-counter (OTC) drugs, and herbal drugs. Based on sleep disorder, it is classified into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleep walking, and other sleep disorder. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market growth is attributed to the surge in prevalence of sleep disorders, rise in geriatric and obese population, and change in lifestyle. The surge in disposable income; increase in awareness about sleep disorders; stressful work issues; enhanced intake of caffeine, tobacco, and alcohol; and technological advancements are expected to boost the sleep aids market growth. However, adverse effects of sleep aids medication in patient with sleep disorders, such as dizziness, diarrhea, constipation, daytime drowsiness; and expiration on sleep drugs patents are expected to hamper the market growth.

KEY MARKET BENEFITS

  • This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations provided are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to product, sleep disorder, and geography.
  • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

  • Koninklijke Philips N.V.
  • Merck & Co.
  • Sanofi
  • DeVilbiss Healthcare LLC.
  • Pfizer Inc.
  • SleepMed Inc.
  • Cadwell Laboratories Inc.
  • Compumedics Limited
  • Natus Medical Incorporated
  • GlaxoSmithKline plc.

Sleep Aids Market Key Segments

BY PRODUCT

  • Mattresses & Pillows
  • Sleep Laboratories
  • Medications
  • Prescription-based drugs
  • OTC drugs
  • Herbal drugs
  • Sleep Apnea Devices

BY SLEEP DISORDER

  • Insomnia
  • Sleep Apnea
  • Restless Legs Syndrome
  • Narcolepsy
  • Sleep Walking
  • Other Sleep Disorders

BY GEOGRAPHY

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Turkey
  • Republic of South Africa
  • Saudi Arabia
  • Rest of LAMEA

The other players of the sleep aids market include (companies not profiled in the report):

  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • CareFusion Corporation
  • Tempur-Pedic Management Inc.
  • Serta International
  • Drive Medical Ltd.

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY BENEFITS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PATENT ANALYSIS
    • 3.3.1. Patent analysis by year
    • 3.3.2. Patent analysis by region
    • 3.3.3. Patent analysis by sleep disorder
  • 3.4. GOVERNMENT REGULATIONS
    • 3.4.1. U.S. FDA
    • 3.4.2. Europe CE Mark
    • 3.4.3. Ministry of Health, Labor, and Welfare (MHLW)
  • 3.5. TOP PLAYERS POSITIONING, 2016
  • 3.6. MARKET DYNAMICS
    • 3.6.1. Drivers
      • 3.6.1.1. Modern lifestyle increases the risk of sleep disorders
      • 3.6.1.2. Stressful Work Condition and Working in Shifts
      • 3.6.1.3. Rise in geriatric and obese population
    • 3.6.2. Restraints
      • 3.6.2.1. Adverse effects of sleep aid medication
      • 3.6.2.2. Patent expiration
    • 3.6.3. Opportunities
      • 3.6.3.1. Technological Advancements Leading to Better Adoption
      • 3.6.3.2. Untapped Markets in Developing Economies

CHAPTER 4 GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. MATTRESSES AND PILLOWS
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. SLEEP LABORATORIES
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. MEDICATIONS
    • 4.4.1. Key market trends
    • 4.4.2. Key growth factors and opportunities
    • 4.4.3. Market size and forecast
    • 4.4.4. Prescription-based drugs
    • 4.4.5. OTC drugs
  • 4.5. SLEEP APNEA DEVICES
    • 4.5.1. Key market trends
    • 4.5.2. Key growth factors and opportunities
    • 4.5.3. Market size and forecast

CHAPTER 5 SLEEP AIDS MARKET, BY SLEEP DISORDER

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. INSOMNIA
    • 5.2.1. Market size and forecast
  • 5.3. SLEEP APNEA
    • 5.3.1. Market size and forecast
  • 5.4. RESTLESS LEGS SYNDROME
    • 5.4.1. Market size and forecast
  • 5.5. NARCOLEPSY
    • 5.5.1. Market size and forecast
  • 5.6. SLEEPWALKING
    • 5.6.1. Market size and forecast
  • 5.7. OTHERS
    • 5.7.1. Market size and forecast

CHAPTER 6 SLEEP AIDS MARKET, BY GEOGRAPHY

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. NORTH AMERICA
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast
      • 6.2.3.1. U.S. market size and forecast
      • 6.2.3.2. Canada market size and forecast
      • 6.2.3.3. Mexico market size and forecast
  • 6.3. EUROPE
    • 6.3.1. Key market trends
    • 6.3.2. Key growth factors and opportunities
    • 6.3.3. Market size and forecast
      • 6.3.3.1. Germany market size and forecast
      • 6.3.3.2. France market size and forecast
      • 6.3.3.3. UK market size and forecast
      • 6.3.3.4. Italy market size and forecast
      • 6.3.3.5. Rest of Europe market size and forecast
  • 6.4. ASIA-PACIFIC
    • 6.4.1. Key market trends
    • 6.4.2. Key growth factors and opportunities
    • 6.4.3. Market size and forecast
      • 6.4.3.1. Japan market size and forecast
      • 6.4.3.2. China market size and forecast
      • 6.4.3.3. Australia market size and forecast
      • 6.4.3.4. India market size and forecast
      • 6.4.3.5. Rest of Asia-Pacific market size and forecast
  • 6.5. LAMEA
    • 6.5.1. Key market trends
    • 6.5.2. Key growth factors and opportunities
    • 6.5.3. Market size and forecast
      • 6.5.3.1. Brazil market size and forecast
      • 6.5.3.2. Turkey market size and forecast
      • 6.5.3.3. Saudi Arabia market size and forecast
      • 6.5.3.4. South Africa market size and forecast
      • 6.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

  • 7.1. CADWELL INDUSTRIES INC.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product portfolio
    • 7.1.5. Business performance
    • 7.1.6. Key strategic moves and developments
  • 7.2. COMPUMEDICS LIMITED
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product portfolio
    • 7.2.5. Business performance
    • 7.2.6. Key strategic moves and developments
  • 7.3. DRIVE DEVILBISS HEALTHCARE
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product portfolio
    • 7.3.5. Business performance
    • 7.3.6. Key strategic moves and developments
  • 7.4. GLAXOSMITHKLINE PLC
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
    • 7.4.6. Key strategic moves and developments
  • 7.5. MERCK & CO., INC.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
    • 7.5.6. Key strategic moves and developments
  • 7.6. NATUS MEDICAL INCORPORATED
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
    • 7.6.6. Key strategic moves and developments
  • 7.7. PFIZER INC.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product portfolio
    • 7.7.5. Business performance
    • 7.7.6. Key strategic moves and developments
  • 7.8. KONINKLIJKE PHILIPS N.V.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product portfolio
    • 7.8.5. Business performance
    • 7.8.6. Key strategic moves and developments
  • 7.9. SANOFI
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Product portfolio
    • 7.9.4. Business performance
    • 7.9.5. Key strategic moves and developments
  • 7.10. SLEEPMED INC.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product portfolio
    • 7.10.5. Business performance
    • 7.10.6. Key strategic moves and developments
Back to Top